Oncology CRO | Charles River Discovery Research Services

Neurotoxicity Model 

Peripheral neurotoxicity occurs in approximately 40 percent of previously untreated cancer patients who receive taxane-containing chemotherapy regimes. Because the effects of this therapy may limit treatment for a significant percentage of patients, the Charles River model that mimics clinical toxicity is significant. The model permits the evaluation of interactions of proposed protectant strategies for the disease and its treatment.

For more information about our neurotoxicity model, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.

Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 13 - High-Throughput Screening for CNS ...
May 08 - Comparability Studies for Monoclon...
May 28-Jun 01 - Kobe, Japan - Joint Meeting of the International Bone and Mineral Socie...
May 27-May 29 - Almere, The Netherlands - Rodent Surgery Hands-on Training (3-day)

Charles River Laboratories, Inc.